Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
1 hedge funds and large institutions have $87 invested in Mersana Therapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 49 closing their positions.
44.91% less ownership
Funds ownership: 44.91% → 0% (-45%)
98% less funds holding
Funds holding: 51 → 1 (-50)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $64.8M → $87 (-$64.8M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 49
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Nextech Invest
Zurich,
Switzerland
|
-$14M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$10M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$4.41M |
| 4 |
AV
Alamea Verwaltungs
Edison,
New Jersey
|
-$3.34M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.21M |
MRSN Hedge Fund Activity: Q1 2026 in Review
1 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q1 2026, worth a combined $87 — down 100% from $64.8M a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of MRSN and 0 opened new positions — a net loss of 49 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Nextech Invest, exiting entirely with an estimated $14M sold.
- 1 institutional investor held Mersana Therapeutics (MRSN) as of Q1 2026, down from 51 in Q4 2025.
- Funds reported $87 of Mersana Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Mersana Therapeutics positions in Q1 2026 and 49 closed out, a net change of -49 holders.
- The largest Mersana Therapeutics seller in Q1 2026 was Nextech Invest, an estimated $14M sold.
Based on aggregated 13F filings for Q1 2026.